Secarna Pharmaceuticals GmbH & Co. KG, a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, and SciNeuro Pharmaceuticals, a company involved in the discovery and development of innovative therapeutics for the treatment of neurological diseases, entered a multi-target research and option agreement.
(RTTNews) - Secarna Pharmaceuticals GmbH & Co. KG and Evotec SE (EVTCY.PK, EVOTF.PK) said that they have expanded their strategic partnership in the field of antisense oligonucleotide - based therapeutics. Terms and conditions of the collaboration were not disclosed.